- In January 2024, the U.S. market saw the launch of the HemoFlow 500 Series, marking a significant advancement in blood scale and mixer technology. These next-generation devices are designed to enhance the efficiency and precision of blood sample processing in clinical and laboratory settings. The launch is expected to improve workflow and accuracy, meeting the growing demands for high-quality blood testing and analysis
- In November 2023, Versiti completed the acquisition of Pearl Pathways, an Indianapolis-based firm specializing in regulatory consulting and clinical trials. This strategic acquisition is aimed at strengthening Versiti's capabilities in advancing regulatory processes and enhancing its research and development efforts. The move is expected to expand Versiti's influence in the field of blood and biopharmaceutical research
- In July 2023, QuidelOrtho announced a collaboration with BYG4lab to enhance its informatics offerings. This partnership is set to integrate innovative data management solutions and digital health technology to streamline laboratory operations. The collaboration aims to improve data accessibility and optimize the quality of diagnostic and transfusion services
- In May 2022, Nihon Kohden Corporation, a leading medical technology company, established a new hematology analyzer reagent factory in India. This strategic expansion is intended to meet the growing demand for advanced diagnostic tools and reagents in the region. The move is expected to strengthen Nihon Kohden's presence and service capabilities within the South Asian market
- In April 2022, Sysmex Europe launched the XQ-320 XQ-Series Automated Hematology Analyzer, a new three-part differential system. This innovative analyzer is equipped with advanced features for quality control and data security, supporting more accurate and efficient patient diagnostics. The XQ-320 is designed to enhance laboratory productivity and improve the safety and reliability of patient data management
- In January 2021, Thermo Fisher Scientific Inc. acquired Mesa Biotech, Inc. to strengthen its molecular diagnostic segment. This strategic move is expected to help the company capture a larger share of the market for PCR-based rapid point-of-care testing solutions
